A new therapeutic target offers a promising pathway for multiple sclerosis treatment

The astroglia (a class of neural cells) of patients with MS overproduce a channel protein known as connexin 43. This overproduction facilitates the release of pro-inflammatory chemicals that trigger a harmful immune response, ultimately causing damage to neurons. In this animal model study of MS, researchers observed that blocking this channel protein with an inhibitor called INI-0602 markedly improved MS symptoms, suggesting the potential of connexin 43 as a new therapeutic target for MS. Credit: Ryo Yamasaki, Kyushu University Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling Read More